<DOC>
	<DOC>NCT00402818</DOC>
	<brief_summary>RESTORE is an observational, open-label, multi-center, prospective, study enrolling Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis. The overall duration of the study is approximately 4 years. Patients will be followed from the time of study enrolment to study/treatment termination; thus active follow-up period will vary across subjects. Raptiva® (efalizumab)treated patients with moderate to severe chronic plaque psoriasis and meeting the inclusion/exclusion criteria specified will be eligible for participation in this study. Objectives: - To document and quantify the incidences of adverse events in this patient population - To explore the association of psoriasis treatments with changes in patient outcomes, quality of life, and treatment compliance.</brief_summary>
	<brief_title>RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or female ≥ 18 years old. Have a clinical diagnosis of moderate to severe chronic plaque psoriasis and be a candidate for treatment with Raptiva®. Are being treated or are initiating treatment with Raptiva® at time of study enrolment in accordance with the Canadian Product Monograph indication and recommendations. Be able to provide written informed consent. Agreement to participate in the study, and to disclose any medical events to the Investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study. Any contraindication to Raptiva® according to the Canadian Product Monograph. Any simultaneous participation in another clinical evaluation trial for psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Moderate to severe plaque psoriasis</keyword>
</DOC>